Cachexia is accountable for multiple adverse outcomes in cancer patients. Muscle wasting is a major feature of aging and cancer cachexia. Mitochondrial dysfunction may be involved in sarcopenia and cancer cachexia. Mitochondrial quality control is altered in old patients with cancer cachexia. Mitochondrial fidelity pathways may be targeted for interventions against cachexia.